Table 2.
Pharmaceutical formulations with proteins and genes targeting neurodegenerative disorders using lipid-based and inorganic nanoparticles.
| Active Molecule | Formulation | Targeting Disease | Method | Ref. |
|---|---|---|---|---|
| BDNF | Mannose functionalized liposomes | AD | In vivo | [125] |
| Vgf (non-acronymic), a neurotrophin-stimulated protein | Liposomes | AD | In vivo C57BL/6J mice |
[126] |
| Retro-inverso peptide RI-OR2-TAT | Liposomes | AD | In vitro | [127] |
| GDNF plasmid- | Pegylated liposomes | PD | In vivo 6-hydroxydopamine (6-OHDA) mice |
[128] |
| NGF gene | 1,2-distearoyl-sn-glycero-3-phosphoethanolamine–poly(ethylene glycol) phospholipid-based liposomes | PD | In vivo C57BL/6J mice |
[129] |
| GDNF | Nanostructured lipid carriers (NLCs) | PD | In vivo MPTP mice |
[130] |
| Conjugated transferrin | Solid lipid nanoparticles (SLNs) | AD | In vitro | [131] |
| Erythropoietin | Solid lipid nanoparticles (SLNs) | AD | In vivo Albino male Wistar rats |
[132] |
| GDNF | Chitosan-coated NLC | PD | In vivo rats |
[133] |
| BACE1 siRNA | Chitosan-coated SLNs | AD | In vitro | [134] |
| siRNA | RGV-anionic liposomes | PD | In vitro | [135] |